GlassScriptPhysician profile
Justin T Lee
NPI 1104913425
$9,604.97
in general payments reported to CMS, 2019-2025
15 companies · $97.58 in 2025
The $97.58 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,782 · 2020: $504 · 2021: $1,425 · 2022: $840 · 2023: $2,449 · 2024: $506 · 2025: $97.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894 · Travel and Lodging: $1,130 · Gift: $28.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.70 |
| Travel and Lodging | $1,130.31 |
| Gift | $28.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $3,653.10 | 2019-2020 | |
| Medtronic, INC. | $3,380.75 | 2021-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $749.05 | 2021-2024 | Solyx Sis System, Advantage System, Upsylon |
| Coloplast Corp | $617.82 | 2020-2024 | Restorelle |
| Intuitive Surgical, INC. | $402.50 | 2019-2023 | Da Vinci Surgical System |
| Hologic Sales and Service, LLC | $131.27 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $124.57 | 2019 | |
| Sumitomo Pharma America, INC. | $124.38 | 2023-2025 | Gemtesa |
| Shockwave Medical, INC | $112.67 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Urovant Sciences INC | $104.01 | 2022 | |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Caldera Medical, INC | $69.03 | 2022-2023 | Desara |
| Ethicon US, LLC | $33.44 | 2024 | Stratafix, Dermabond |
| Axonics, INC. | $24.81 | 2021 | |
| Abbott Laboratories | $2.58 | 2024 | Emboshield Nav6 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.